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Abstract: Bronchiectasis is defined by permanent and abnormal widening of the bronchi. 
This process occurs in the context of chronic airway infection and inflammation. It is usually 
diagnosed using computed tomography scanning to visualize the larger bronchi. Bronchiectasis 
is also characterized by mild to moderate airflow obstruction. This review will describe the 
pathophysiology of noncystic fibrosis bronchiectasis. Studies have demonstrated that the small 
airways in bronchiectasis are obstructed from an inflammatory infiltrate in the wall. As most 
of the bronchial tree is composed of small airways, the net effect is obstruction. The bronchial 
wall is typically thickened by an inflammatory infiltrate of lymphocytes and macrophages which 
may form lymphoid follicles. It has recently been demonstrated that patients with bronchiectasis 
have a progressive decline in lung function. There are a large number of etiologic risk factors 
associated with bronchiectasis. As there is generally a long-term retrospective history, it may 
be difficult to determine the exact role of such factors in the pathogenesis. Extremes of age and 
smoking/chronic obstructive pulmonary disease may be important considerations. There are 
a variety of different pathogens involved in bronchiectasis, but a common finding despite the 
presence of purulent sputum is failure to identify any pathogenic microorganisms. The bacterial 
flora appears to change with progression of disease.
Keywords: bronchiectasis, inflammation, obstructive lung disease, pathophysiology, pathology
Introduction
Bronchiectasis is defined by the presence of permanent and abnormal dilation of 
the bronchi.1,2 This usually occurs in the context of chronic airway infection causing 
inflammation. The main clinical manifestation is a productive cough. Bronchiectasis is 
currently nearly always diagnosed using high-resolution computed tomography (HRCT) 
scanning. The main diagnostic features are: 1) internal diameter of a bronchus is wider 
than its adjacent pulmonary artery; 2) failure of the bronchi to taper; and 3) visualiza-
tion of bronchi in the outer 1–2 cm of the lung fields.3 This review will describe the 
pathophysiology of noncystic fibrosis (CF) bronchiectasis.
With the widespread availability of HRCT it has been realized that bronchiectasis 
remains a common and important cause of respiratory disease. It has been estimated 
that there are at least 110,000 adults in the United States with this condition.4 In addi-
tion, there is overlap with chronic obstructive pulmonary disease (COPD) with two 
studies reporting an incidence of bronchiectasis in COPD as being 29%5 and 50%,6 
respectively.
Bronchiectasis is characterized by mild to moderate airflow obstruction7–11 that 
tends to worsen over time.12–14 The most widely known model of the development of International Journal of COPD 2009:4 412
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bronchiectasis is Cole’s “vicious cycle hypothesis”.15 In this 
model, Cole proposed that an environmental insult often 
on a background of genetic susceptibility impaired muco-
ciliary clearance resulting in persistence of microbes in the 
sinobronchial tree and microbial colonization. The microbial 
infection caused chronic inflammation resulting in tissue 
damage and impaired mucociliary motility. In turn this led 
to more infection with a cycle of progressive inflammation 
causing lung damage. The current view is that the two factors 
required for the development of this condition are persistent 
infection and a defect in host defense.
There are no well established animal models of bron-
chiectasis nor have there been studies performed in the 
early stages of the disease. Bronchiectasis is also a very 
heterogeneous condition and can be considered the end 
result of a variety of different factors. As a consequence the 
pathophysiologic processes are still not well defined. This 
review will discuss different aspects in which this condition 
may develop.
Pathology
Most studies of the pathology of bronchiectasis were reported 
between 1930 and 1960 as there was access to significant 
quantities of operative and postmortem lung specimens at this 
time. Reid categorized bronchiectasis as having three main 
phenotypes: 1) tubular characterized by smooth dilation of 
the bronchi; 2) varicose in which the bronchi are dilated with 
multiple indentations; and 3) cystic in which dilated bronchi 
terminate in blind ending sacs.16 The current major form 
seen on HRCT is the tubular form of bronchiectasis. The CT 
appearance of these three different forms of bronchiectasis 
is demonstrated in Figure 1.
Arguably the most definitive study of the pathology of 
bronchiectasis was performed by Whitwell17 who studied 
200 consecutive operative lung specimens. This study 
demonstrated marked inflammation of the bronchial wall, 
principally in the smaller airways. Bronchial dilation was 
characterized by deficiency/loss of elastin and more advance 
disease by destruction of muscle and cartilage. The specific 
mechanism of how this loss of tissue leads to bronchial 
dilatation is not known. There was variable bronchial wall 
fibrosis, atelectasis and peribronchial pneumonic change. 
Whitwell classified bronchiectasis into three different types: 
follicular, saccular, and atelectatic. Follicular bronchiectasis 
was the dominant form and this corresponded to tubular 
bronchiectasis (the main form commonly seen).
Figure 1 HrCT examples of reid’s three forms of bronchiectasis: A) tubular B), varicose, and C) cystic.
Abbreviation: HrCT, high-resolution computed tomography.International Journal of COPD 2009:4 413
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Follicular bronchiectasis was characterized by the 
presence of lymphoid follicles in the bronchial wall. The 
inflammatory process commenced in the small airway. This 
small airway inflammation caused the release of mediators 
such as proteases which damaged the large airways causing 
loss of elastin and other components such as muscle and 
cartilage which resulted in bronchial dilation. With progres-
sion of the disease lymphoid follicles enlarged in size and 
caused airflow obstruction to the small airways. The final 
event was spread of the inflammation beyond the airways to 
cause interstitial pneumonia. This process is demonstrated in 
Figure 2. Recently Hogg and colleagues18 described similar 
lymphoid follicles in chronic obstructive pulmonary disease 
(COPD) which had a strong association with bronchial wall 
thickening and airflow obstruction.
The dominant cell types involved in the inflammatory 
process in bronchiectasis are neutrophils, lymphocytes, and 
macrophages.19 Neutrophils are the most prominent cell type 
in the bronchial lumen20,21 and release mediators, particularly 
proteases/elastase which cause bronchial dilation (ie, bron-
chiectasis).22,23 The infiltrate in the cell wall is predominantly 
composed of macrophages and lymphocytes.20,24 Studies have 
reported that the main lymphocyte is the T cell24,25 and these 
are cells that are likely to produce the lymphoid follicles 
described by Whitwell.
Emphysema may also occur in bronchiectasis. Loubeyre 
and colleagues26 reported that half of a cohort of subjects 
had localized emphysema in association with bronchiectasis. 
This presumably corresponds to the interstitial pneumonia 
described by Whitwell that spreads into the parenchyma of 
the lungs to cause localized damage.
Distribution of bronchiectasis
The distribution of bronchiectasis may be associated with 
different pathophysiologic processes eg, allergic bronchop-
ulmonary aspergillosis is classically associated with central 
bronchiectasis. Bronchiectasis has been described as being 
localized (ie, confined to one lobe) or generalized. Most 
commonly it is generalized and seems to be most com-
mon in the lower lobes.2,27 The involvement of the lower 
lobes may reflect gravity dependent retention of infected 
secretions.
Right middle lobe bronchiectasis has been well described 
in the context of tuberculosis.17,28–32 The right middle lobe 
bronchus is long, often bends sharply at its bifurcation and is 
of relatively small caliber. A collar of lymph nodes also sur-
rounds the proximal bronchus and any condition that causes 
a prolonged enlargement of these nodes may lead to obstruc-
tion and secondary bronchiectasis. This may also occur in 
malignancy33 and in nontuberculous mycobacterial infection 
Small airway A) Large airway Small airway
Proteases
Inflammation Inflammation
Obstruction Dilation (bronchiectasis) Dilation (bronchiectasis)
Dilation (bronchiectasis)
Obstruction
Interstitial pneumonia
B)
D) C)
Figure 2 Pathologic changes in follicular bronchiectasis as described by whitwell. A) The first process involves infection of the small airways. B) This leads to the release of 
inflammatory mediators such as proteases which damage the large airways resulting in bronchial dilation and bronchiectasis. C) Infection drives progressive inflammation in the 
small airways which become thicker from a combination of cell-mediated inflammatory infiltrate and lymphoid follicles resulting in obstruction. D) The final process involves 
the spread of inflammation beyond the airways resulting in interstitial pneumonia.International Journal of COPD 2009:4 414
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(often with the lingula lobe).34 This event is demonstrated 
in Figure 3.
It is generally not known if bronchiectasis starts in one 
section of the respiratory tract and then spreads or if it begins 
as a generalized process. Childhood bronchiectasis has a high 
proportion of subjects who have chronic rhinosinusitis as 
well.10,27,35 One report described the apparent spread of sinus 
infection to the lungs resulting in bronchiectasis.36
Lung function
A number of studies have described the lung function in 
bronchiectasis. Patients usually have mild to moderate air-
flow obstruction. It has also been demonstrated recently that 
there is a progressive decline in lung function over time with 
loss of forced expiratory volume in one second (FEV1).12–14 
This is a paradoxical finding as the characteristic feature of 
bronchiectasis is airway dilation.
A CT/lung function study found that airflow obstruction in 
bronchiectasis was predominantly due to small and medium 
airway involvement with features of decreased attenuation 
and mucosal wall thickening. The decreased attenuation 
was a marker of small airway constrictive bronchiolitis. The 
small airway constrictive bronchiolitis is diagnosed by the 
presence of a mosaic pattern on expiratory films.37
The pathology studies by Whitwell explain the finding 
of airflow obstruction in bronchiectasis. These studies 
show the large airways become dilated but the small and 
medium airways are characterized by airflow obstruction 
predominantly arising from thickening of the bronchial wall. 
As most of the respiratory tree is composed of medium and 
small airways the net effect of the inflammatory process in 
bronchiectasis is airflow obstruction (Figure 2).
Etiologic factors
There have been a large number of factors that have been 
described as causative for bronchiectasis. A problem with 
assigning these factors as being causative is that subjects 
have usually had their lung disease for a long time (often 
more than 10 years) and the attribution may rely on long-term 
retrospective recall. It may perhaps be more appropriate to 
consider them as risk factors rather than the definitive cause. 
The etiologic factors that have been described generally all 
have some role in impairing host defence to infection. Some 
important etiologic factors are discussed below. A list of 
etiologic factors is given in Table 1.
Postinfectious
The most common cause of bronchiectasis is the literature 
is postinfectious. This is not a well defined entity but the 
usual context appears to be one acute infectious episode 
which is thought to result in bronchiectasis. To the author’s 
knowledge, the development of bronchiectasis after one 
infectious episode have not been definitively demonstrated 
in a cohort of patients. At some stage all bronchiectasis 
patients become colonized with bacteria but this appears to 
be a little different from acute process in the postinfectious 
entity that is described in the literature. A possible mechanism 
for postinfectious bronchiectasis is a significant infection 
in early childhood which causes structural damage to the 
developing lung and permits bacterial infection which is 
A) B)
Figure 3 Pathologic process in the right middle lobe with mycobacterial infection. A) Infection causes enlargement of peribronchial lymph nodes resulting in obstruction. 
B) The obstruction results in bronchiectasis that persists when the nodes return to normal size.International Journal of COPD 2009:4 415
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not cleared. Over time persistent infection may then result 
in bronchiectasis.
One well characterized form of bronchiectasis occurs 
in the context of mycobacterial infection and this form is 
particularly prevalent in the right middle lobe with nontuber-
culous mycobacterium.17,38,39 The mechanism of this form of 
bronchiectasis appears to arise from lymph node obstruction. 
The acute infection causes enlargement of peribronchial 
nodes which obstruct the bronchus and result in secondary 
bronchiectasis. This bronchial dilation persists when the 
mycobacterial infection resolves and the nodes return to 
normal size. This process is demonstrated in Figure 3.
Muco-ciliary clearance
Muco-ciliary clearance is a key defence mechanism against 
pulmonary infection. Its compromise is important in the 
development of the vicious cycle of bronchiectasis as pro-
posed by Cole.15 Cystic fibrosis is associated with defective 
muco-ciliary clearance but this area is beyond the scope of 
the current review. There has been renewed interest recently 
in ciliary defects and this has been recently reviewed.40–42 The 
most prominent cilial disorder is primary ciliary dyskinesia 
(PCD) which combines upper and lower respiratory tract 
infection, male infertility and in approximately 50%, situs 
inversus. PCD arises primarily from a defect in the dynein 
arms which are necessary for normal cilial beating. This area 
has been the subject of recent discoveries.43,44 Bronchiectasis 
is a prominent manifestation of PCD. The definitive diagnosis 
of PCD requires electron microscopy to demonstrate loss of 
dynein and this requires specialized expertise available only 
in a limited number of centers. Screening can be undertaken 
more easily using nasal nitric oxide and in vivo tests of ciliary 
motility such as the saccharin test. Young’s syndrome is 
another condition in which the primary defect is thought to 
be defective mucous function.45
Malnutrition/socioeconomic
Bronchiectasis has been described as being a major problem 
in developing nations although the prevalence has not been 
well defined. Authors from South America,46 Hong Kong/
China,47 India,48 and Turkey49 all report that bronchiectasis is 
an important local problem. It is certainly a major problem in 
certain indigenous populations such as Australian aborigines, 
New Zealand Maori, and Alaskan natives.50–52 A common 
feature of these groups is malnutrition and social disadvan-
tage which are likely to be associated with impaired immune 
function (Torzillo and Chang, pers comm.).53 Malnutrition/
socioeconomic disadvantage is not commonly listed as an 
etiologic factor for bronchiectasis, but in selected populations 
it may be important.
extremes of age
The immune system is less effective in young children and eld-
erly adults which results in an increased incidence of infection 
in these two groups.54,55 Bronchiectasis has most commonly 
been described as commencing in childhood, particularly 
in the first five years of life, with chronic productive cough 
and unresolved infection.2,10,27 Field performed a long-term 
prospective follow-up on 225 patients with bronchoscopy. 
She found that 74% of the cohort had the onset of chronic 
respiratory infection in the first five years of life and subjects 
tended to significantly improve in late adolescence regardless 
of treatment.27 Our group has studied adult patients with bron-
chiectasis who had the onset of symptoms in childhood.2 Most 
of these subjects (about two-thirds) described the improvement 
of their symptoms in late adolescence and then a worsening of 
their symptoms from the age of 50 to 60 years when they repre-
sented for medical assessment. These two studies suggest that 
a common feature of childhood-onset bronchiectasis may be 
an improvement with adulthood and then clinical deterioration 
again beyond the age of 50 years. This is shown in Figure 4.
We have also described the phenotype of patients who first 
develop bronchiectasis in adulthood.35 The onset of chronic 
chest suppuration cough was uncommon from the ages of 
15–50 years. Eighty-one percent of adult-onset patients had 
the onset of chronic chest suppuration over the age of 50 years. 
Weycker and colleauges report a prevalence of bronchiectasis 
as being 4.2 per 100,000 persons aged 18 to 34 years and 272 
per 100,000 in those aged over 75 years.4 Therefore extremes 
Table 1 etiologic/risk factors associated with bronchiectasis
Postinfective (postpneumonia, whooping cough, measles, mycobacterial 
infection)
Mucociliary disorder (immotile cilia, Kartagener’s syndrome, Young’s 
syndrome)
Obstructive (foreign body, mycobacterial infection, obstructing cancer)
Immune disorder (hypogammaglobulinemia, HIv infection, cancer, allergic 
bronchopulmonary aspergillosis, transplant rejection)
Rheumatic/inflammatory disease (rheumatoid arthritis, inflammatory 
bowel disease)
extremes of age
Malnutrition/socioeconomic disadvantage
Chronic obstructive pulmonary disease
Aspiration
Alpha1-antitrypsin deficiency
Miscellaneous (yellow nail syndrome)International Journal of COPD 2009:4 416
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of age may be important in the development and clinical 
manifestations of bronchiectasis. Increasing age has been 
recently described as being an important factor in COPD.56
Chronic obstructive pulmonary disease
A cardinal feature of COPD is the presence of chronic 
bronchitis. Recently two studies have reported a high inci-
dence of bronchiectasis in COPD patients. O’Brien and 
colleagues5 studied 110 patients with COPD who presented 
with an acute exacerbation in a primary care setting and found 
HRCT evidence of bronchiectasis in 29% of the cohort. Patel 
and colleagues6 studied 54 patients with severe COPD for 
the presence of bronchiectasis. They found that 50% of the 
patients had co-existent bronchiectasis and this was associ-
ated with bacterial airway colonization and inflammatory 
markers and longer duration of exacerbations.6 Patients with 
COPD and bronchiectasis tend to have more dyspnea, worse 
lung function, and a lack of upper airway involvement when 
compared to other bronchiectasis subjects.35
There is also some overlap in the pathology of COPD 
and bronchiectasis. Both conditions have neutrophils and 
T lymphocytes as the predominant inflammatory cell,19,57 
protease release causes pulmonary damage and lymphoid 
follicles have a role in airflow obstruction.17,18
Immune dysfunction
The term immune dysfunction covers a wide variety of causes 
but some conditions associated with bronchiectasis are pri-
marily categorized as immune dysfunction disorders. These 
can be considered in terms of primary immune deficiencies 
such as hypogammaglobulinemia, human immunodeficiency 
virus (HIV), interferon gamma receptor deficiency, and type I 
major histocompatibility complex deficiency.2 Detection of 
hypogammaglobulinemia is important as replacement therapy 
may have therapeutic implications. The clinical significance 
of immunoglobulin subclass deficiency is controversial.
Bronchiectasis may occur in the late stages of lung 
transplant rejection. Allergic bronchopulmonary aspergil-
losis (ABPA) is a classic cause of bronchiectasis and this is 
important to diagnose as there are specific ramifications for 
treatment. Bronchiectasis may also occur in subjects with 
very high levels of immunoglobulin E but without ABPA.36
Mycobacterial infections have been recognized to be 
associated with bronchiectasis, particularly in older women 
where the combination of mycobacterium avium complex 
(MAC) infections causing obstruction from lymphad-
enopathy with right middle lobe bronchiectasis is a well 
described syndrome.58,59 It should also be remembered that 
MAC infections are opportunistic and may cause infection 
in other chronic lung diseases such as COPD and therefore 
infection with MAC may be secondary to bronchiectasis. It 
is not clear from the literature what the effect of secondary 
MAC colonization is on the progression of bronchiectasis. In 
four children who had disseminated mycobacterial infection, 
researchers recently found a mutation defect in the gene for 
interferon gamma receptor, the primary protective cytokine 
against intracellular mycobacterial infection.60
Rheumatological/inflammatory conditions
There is a well described association between bronchiectasis 
and rheumatoid arthritis. In rheumatoid arthritis the incidence 
of bronchiectasis has been described to be 1%–3%. Recent 
studies of patients with rheumatoid arthritis have described 
the prevalence of bronchiectasis on HRCT in such patients 
as being up to 30%.61,62 Bronchiectasis is described as pre-
ceding and occurring after the development of rheumatoid 
arthritis. Bronchiectasis may also occur in association with 
Sjogren’s syndrome63 and Churg–Strauss syndrome.64 It is 
possible that immune suppression may predispose to chronic 
airway infection.64 Bronchiectasis also occurs in subjects 
with inflammatory bowel disease.65
Alpha1-antitrypsin deficiency
Alpha1-antitrypsin deficiency (AAT) is associated with 
increased risk of COPD and bronchiectasis. Parr and col-
leagues studied the prevalence of airways disease in AAT-
deficient subjects and found that 70 of 74 subjects had 
radiological evidence of bronchiectasis and 20 subjects were 
classified as having clinically significant bronchiectasis.66
Symptoms and age
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Figure 4 Change in severity of symptoms over time in those with childhood-onset 
bronchiectasis. A common finding in subjects whose symptoms began in childhood 
is improvement in late adolescence and then deterioration again from about the age 
of 50 years.International Journal of COPD 2009:4 417
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Microbiology
A large number of different pathogens have been isolated in 
studies of microbiologic flora in bronchiectasis. There is often 
significant variation between different locations. The main 
findings from recent studies have been that Haemophilus influ-
enzae is the most common pathogen (range 29%–70%) fol-
lowed by Pseudomonas aeruginosa (range 12%–31%).7,10,67–71 
The other major finding of these studies is that 30%–40% of 
sputum samples despite being good quality and purulent will 
fail to grow any pathogenic bacteria; and this applies even 
when bronchoscopy and protected brush/bronchoalveolar 
lavage is used. The bronchi also have a dynamic turnover of 
pathogens. A two-year prospective study found that a propor-
tion of patients were continually colonized by Branhamella 
catarrhalis (the name Branhamella has recently been changed 
to Moxarella) but there was a continous turnover of strains 
every 2–3 months.72 In COPD, there is evidence for consider-
able turnover of bacteria with the acquisition of new strains 
demonstrated to be associated with exacerbations.73
An important finding of bronchiectasis is that there 
appears to be a change in microbial flora with severity of 
disease.71 Typically subjects with the best preserved lung 
function are most likely to have no pathogenic bacteria 
isolated. As lung function declines H. influenzae becomes 
predominant and finally in patients with the most severe 
disease the usual pathogen isolated is P . aeruginosa.
Specific pathogens
H. influenzae is the most common isolate and is nearly always 
the nontypeable form (NTHi). P . aeruginosa is associated with 
more sputum, more extensive bronchiectasis, more hospitali-
zations and worse quality of life. Nontuberculous mycobacte-
rial infection may be important in bronchiectasis but studies 
have reported variable prevalence of 2%71,74 to 10%.75
The role of viral infection in bronchiectasis is not well 
defined. Becroft76 identified adenovirus as a risk factor 
for the development of bronchiectasis in young children. 
Influenzae A infection in vitro inhibits neutrophil function 
in bronchiectasis subjects.77 Viral infections have a role in 
exacerbations of COPD but this has not been defined for 
bronchiectasis.78
effects of bacterial pathogens  
on the respiratory tract
Bacterial pathogens may exert a number of direct effects 
on the respiratory tract that impairs host defence. The most 
well described effects in bronchiectasis are inhibition of the 
mucociliary clearance. Mediators released by H. influenzae, 
P . aeruginosa, and Streptococcus pneumoniae may directly 
interfere with ciliary function, damage ciliated epithelium, 
and inhibit mucous transport.79 Bacteria release products such 
as glycoproteins which attract neutrophils. H. influenzae has 
the capacity to cause direct damage to airway epithelium and 
is also able to invade into the bronchial wall and intersti-
tium of the lung.80,81 P. aeruginosa has the capacity to form 
biofilms.82 Biofilms occur particularly in advanced disease 
and form an impenetrable matrix around the Pseudomonas, 
shielding it from the effects of the immune system and anti-
biotics and allowing the bacterial infection to cause severe 
damage to the underlying lung.
Conclusions
Bronchiectasis is characterized by airway inflammation. The 
inflammation appears to arise as a combination of immune 
deficiency and persistent infection. As proposed by Cole this 
inflammatory process is progressive and results in a cycle of 
worsening pulmonary damage. Patients develop progressive 
obstructive lung disease. The airflow obstruction appears to 
arise predominantly from involvement of the small airways 
in which the bronchial wall is infiltrated by inflammatory 
cells particularly lymphocytes which may form lymphoid 
follicles.
Bronchiectasis is a heterogeneous condition and there 
are a large number of etiologic factors have been described. 
Because of the long-term nature of the disease it is often 
hard to be clear about the exact role of such factors in the 
pathogenesis. It may be more appropriate to consider them as 
being risk factors rather than the single cause of longstanding 
airway infection.
The microbiology of bronchiectasis is complex and varies 
significantly between different studies. An important finding is 
that despite purulent sputum and optimal collection techniques 
(eg, bronchoscopy) there is often failure to isolate a pathogenic 
microorganism. The role of viruses is not well understood. 
A better understanding of the microbiology of bronchiectasis 
would have direct implications for patient treatment.
Bronchiectasis is a complex condition and the pathophysi-
ology is still not well understood. Defining the inflammatory 
process particularly before there is significant lung disease 
may be helpful in developing better strategies of treatment.
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